Amedisys Beats Estimates But Has a Big Earnings Drop
Amedisys (NAS: AMED) reported earnings on July 31. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Amedisys missed estimates on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped significantly. Non-GAAP earnings per share contracted significantly. GAAP earnings per share dropped significantly.
Gross margins increased, operating margins dropped, net margins shrank.
Amedisys recorded revenue of $313.1 million. The 11 analysts polled by S&P Capital IQ wanted to see revenue of $328.0 million on the same basis. GAAP reported sales were 16% lower than the prior-year quarter's $373.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
EPS came in at $0.17. The 11 earnings estimates compiled by S&P Capital IQ predicted $0.10 per share. Non-GAAP EPS of $0.17 for Q2 were 37% lower than the prior-year quarter's $0.27 per share. GAAP EPS of $0.06 for Q2 were 77% lower than the prior-year quarter's $0.26 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the quarter, gross margin was 43.8%, 60 basis points better than the prior-year quarter. Operating margin was 1.2%, 300 basis points worse than the prior-year quarter. Net margin was 0.6%, 150 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $325.5 million. On the bottom line, the average EPS estimate is $0.13.
Next year's average estimate for revenue is $1.32 billion. The average EPS estimate is $0.47.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 803 members out of 889 rating the stock outperform, and 86 members rating it underperform. Among 213 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 186 give Amedisys a green thumbs-up, and 27 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amedisys is hold, with an average price target of $9.11.
Is Amedisys the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Amedisys to My Watchlist.
The article Amedisys Beats Estimates But Has a Big Earnings Drop originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.